Marniza Saad

1.6k total citations
51 papers, 425 citations indexed

About

Marniza Saad is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Marniza Saad has authored 51 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in Marniza Saad's work include Prostate Cancer Treatment and Research (19 papers), PARP inhibition in cancer therapy (10 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Marniza Saad is often cited by papers focused on Prostate Cancer Treatment and Research (19 papers), PARP inhibition in cancer therapy (10 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Marniza Saad collaborates with scholars based in Malaysia, United States and United Kingdom. Marniza Saad's co-authors include Vivek Ajit Singh, Nur Aishah Mohd Taib, Jayalakshmi Pailoor, Cheng Har Yip, Anita Zarina Bustam, Effat Omar, Shahneen Sandhu, David Olmos, Guilhem Roubaud and Eric J. Small and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Marniza Saad

46 papers receiving 420 citations

Peers

Countries citing papers authored by Marniza Saad

Since Specialization

Citations

This map shows the geographic impact of Marniza Saad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marniza Saad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marniza Saad more than expected).

Fields of papers citing papers by Marniza Saad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marniza Saad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marniza Saad. The network helps show where Marniza Saad may publish in the future.

Co-authorship network of co-authors of Marniza Saad

This figure shows the co-authorship network connecting the top 25 collaborators of Marniza Saad. A scholar is included among the top collaborators of Marniza Saad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marniza Saad. Marniza Saad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Selective treatment de‐escalation in advanced prostate cancer: have we come full circle? 2025 ·British Journal of Urology ·Bryan Chong, Marniza Saad, Tsung Wen Chong, John P.H. Th'ng, Yu Guang Tan, Kae Jack Tay, Christopher Cheng, Po‐Hung Lin, Jeremy Yuen‐Chun Teoh, Peter Ka‐Fung Chiu, Nathan Lawrentschuk, Renu Eapen, Declan G. Murphy, (unknown), Melvin L.K. Chua, Jeffrey Tuan, John Chi–Hang Yuen, Ravindran Kanesvaran, Kenneth Chen	1
2	Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial 2025 ·European Urology Oncology ·Kim N., Elena Castro, G. Attard, Matthew R. Smith, Shahneen Sandhu, Eleni Efstathiou, Guilhem Roubaud, Eric J. Small, (unknown), Dana E. Rathkopf, Marniza Saad, Howard Gurney, Wonho Jung, Won Kim, Shiva Dibaj, Daphne Wu, Jenny Zhang, Angela Lopez‐Gitlitz, Peter Francis, David Olmos	1
3	Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial 2024 ·European Urology ·Dana E. Rathkopf, Guilhem Roubaud, Kim N., Eleni Efstathiou, Gerhardt Attard, David Olmos, Eric J. Small, Marniza Saad, Elena Castro, Won Kim, Daphne Wu, (unknown), Shiva Dibaj, Jenny Zhang, Peter Francis, Matthew R. Smith	5
4	Antibody Response Following COVID-19 Vaccination in Malaysian Cancer Patients and Healthy Individuals 2024 ·Cureus ·(unknown), (unknown), Gin Gin Gan, Marniza Saad, (unknown), Adaikalavan Ramasamy, I‐Ching Sam, Yek‐Ching Kong, (unknown), Yoke Fun Chan, (unknown), (unknown), Mahmoud Danaee, Cheng Har Yip, Carla H. van Gils, Nirmala Bhoo‐Pathy	0
5	The impact of uro-oncology multidisciplinary team meeting (MDTM) on clinical decision-making and adherence to MDTM recommendation: experience from a tertiary referral centre in Malaysia 2024 ·African Journal of Urology ·(unknown), (unknown), Chu Ann Chai, (unknown), Ahmad Nazran Fadzli, (unknown), Marniza Saad, (unknown)	2
6	COVID-19 Testing Behavior as a Predictor of COVID-19 Vaccination in Southeastern Louisiana: A Longitudinal Cohort Study 2024 ·Vaccines ·Sara Al-Dahir, (unknown), (unknown), (unknown), (unknown), (unknown), Islam Hamed, Linda Cosenza, (unknown), Marniza Saad, (unknown), (unknown), Daniel F. Sarpong, Daniel A. Salmon	1
7	LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE 2023 ·Annals of Oncology ·(unknown), Elena Castro, Gerhardt Attard, Matthew R. Smith, Shahneen Sandhu, Eleni Efstathiou, Guilhem Roubaud, Eric J. Small, (unknown), Dana E. Rathkopf, Marniza Saad, Howard Gurney, Wonho Jung, Gary Mason, Shiva Dibaj, Daphne Wu, B. Diorio, Angela Lopez‐Gitlitz, (unknown), David Olmos	6
8	1806P Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial 2023 ·Annals of Oncology ·G. Attard, Shahneen Sandhu, Dana E. Rathkopf, Elena Castro, Marniza Saad, Mitchell R. Smith, Eric J. Small, David Olmos, (unknown), Guilhem Roubaud, Bogdan Żurawski, Eleni Efstathiou, Daphne Wu, B. Diorio, Karen Urtishak, Umesh Singh, Yan Xu, Angela Lopez‐Gitlitz, (unknown), K.N. Chi	2
9	Novel hormonal therapies in the management of advanced prostate cancer: extrapolating Asian findings to Southeast Asia 2023 ·BMC Urology ·Teng Aik Ong, Marniza Saad, Jasmine Lim, (unknown)	4
10	Evaluation of intrafractional prostate displacement during prostate radiotherapy using real-time ultrasound system 2023 ·Physical and Engineering Sciences in Medicine ·(unknown), Marniza Saad, Adlinda Alip, (unknown), (unknown), (unknown), Yih Miin Liew, Ngie Min Ung	1
11	Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review 2022 ·Therapeutic Advances in Medical Oncology ·Marniza Saad, Rainy Umbas, Edmund Chiong, Ravindran Kanesvaran	4
12	Quality of Life of Family Caregivers of Cancer Patients in a Developing Nation 2022 ·Asian Pacific Journal of Cancer Prevention ·Gin Gin Gan, (unknown), Sumaiyah Mat, Marniza Saad, Ping Chong Bee, Rozita Abdul Malik, Gwo Fuang Ho, Chong Guan Ng	5
13	Proposal for development of a guideline in maintaining quality cancer care during and post-covid-19 in an upper middle-income country with universal health coverage 2021 ·Journal of Cancer Policy ·(unknown), (unknown), Feisul Idzwan Mustapha, Cheng Har Yip, Marniza Saad, (unknown), (unknown), Nik Daliana Nik Farid, Nirmala Bhoo‐Pathy	1
14	Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high‐ and middle‐income Asian countries 2021 ·Cancer Science ·Jasmine Lim, Mizuki Onozawa, Marniza Saad, Teng Aik Ong, (unknown), (unknown), (unknown), (unknown), (unknown)	12
15	Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience 2018 ·Journal of Cancer Research and Therapeutics ·(unknown), Adlinda Alip, Teng Aik Ong, Ning Yi Yap, Marniza Saad	2
16	Impact of adjuvant chemotherapy on survival of women with T1N0M0, hormone receptor negative breast cancer 2017 ·Cancer Epidemiology ·(unknown), (unknown), (unknown), Shiro Tanaka, Nur Aishah Mohd Taib, Cheng Har Yip, Marniza Saad, Koji Kawakami, (unknown), (unknown)	7
17	Monte Carlo skin dose simulation in intraoperative radiotherapy of breast cancer using spherical applicators 2017 ·Physics in Medicine and Biology ·F. Moradi, Ngie Min Ung, Mayeen Uddin Khandaker, Ghafour Amouzad Mahdiraji, Marniza Saad, Rozita Abdul Malik, Anita Zarina Bustam, (unknown), D.A. Bradley	38
18	Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice 2015 ·Asian Pacific Journal of Cancer Prevention ·(unknown), (unknown), (unknown), Anita Zarina Bustam, Marniza Saad, Adlinda Alip, Wan Zamaniah Wan Ishak	1
19	Risk of Treatment Related Death and Febrile Neutropaenia with First Line Palliative Chemotherapy for De Novo Metastatic Breast Cancer in Clinical Practice in a Middle Resource Country 2015 ·Asian Pacific Journal of Cancer Prevention ·(unknown), (unknown), Mastura Md Yusof, Marniza Saad, Adlinda Alip, Mee‐Hoong See, Nur Aishah Mohd Taib	2
20	Risk of Treatment Related Death and Febrile Neutropaenia with Taxane-Based Adjuvant Chemotherapy for Breast Cancer in a Middle Income Country Outside a Clinical Trial Setting 2012 ·Asian Pacific Journal of Cancer Prevention ·(unknown), Anita Zarina Bustam, Mastura Md Yusof, Marniza Saad, Cheng Har Yip, Nur Aishah Mohd Taib, (unknown), (unknown)	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact